Il farmaco ha fallito l'obiettivo di ridurre i decessi cardiovascolari e le recidive di problemi cardiaci in una sperimentazione di fase avanzata

A late-stage clinical trial failed to miss its primary endpoint, U.K.'s laregst drugmaker said Thursday.

Drug developed with Ionis could not reduce cardiovascular deaths or recurring heart problems